Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
The demonstration marks a significant milestone for Lantern Pharma as it transitions withZeta.ai from an internal research tool to a commercially available platform for the global biomedical and drug development community. By offering the platform on a subscription basis, the company aims to generate a new revenue stream while enabling researchers worldwide to leverage its advanced AI capabilities. The platform’s ability to process and analyze diverse datasets—including clinical trial data, genomic profiles, and scientific literature—could reduce the time and cost associated with traditional drug discovery, especially in therapeutic areas with high unmet needs such as rare cancers.
Lantern Pharma is a clinical-stage precision oncology company that utilizes AI, machine learning, and its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The withZeta.ai platform represents a strategic expansion for Lantern beyond its internal pipeline. By commercializing the AI co-scientist, the company positions itself to benefit from the growing demand for AI-driven drug discovery tools. The platform’s multi-agentic architecture allows it to automate and optimize complex research workflows, potentially enabling faster identification of drug candidates and more efficient trial designs. This could be particularly impactful for rare cancers, where limited patient populations and heterogeneous biology often impede traditional drug development.
The live demonstration is expected to attract a global audience of researchers, pharmaceutical executives, and investors interested in the practical applications of AI in oncology. Lantern’s ability to execute a real-time, interactive showcase may help validate the platform’s capabilities and drive adoption. The event also underscores the company’s commitment to transparency and engagement with the scientific community.
For more information on the demonstration and Lantern Pharma’s initiatives, the full press release is available at https://ibn.fm/wzevl. Additional updates on LTRN can be found in the company’s newsroom at https://ibn.fm/LTRN.
